Current News

Print version | PDF version | Send article | RSS feed

Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore

23 Aug 2007 - Merck & Co., Inc, operating in Asia Pacific under the corporate name, Merck Sharp & Dohme (MSD), announced it has opened its regional headquarters in Singapore at Parkview Square. The move is part of the Company's global strategy to strengthen its focus on emerging markets, bringing Merck's portfolio of pharmaceuticals and vaccines to patients and the medical community in Asia.
 
"Singapore is the ideal location for Merck's Asia Pacific regional headquarters because of its favorable business environment," said Mr. Richard T. Clark, chairman, president and CEO, Merck & Co., Inc. "Singapore offers strong intellectual property protection, modern physical and regulatory infrastructure, and a highly-skilled and educated professional workforce. We have also found great support from the EDB to move forward as soon as possible. Merck's decision to relocate our Asia Pacific regional headquarters to Singapore is bold testimony to our long-term confidence in and commitment to Singapore and the entire region."
 
The total investment in Singapore arising out of the relocation will supplement initiatives ongoing in Singapore, including chemical and pharmaceutical operations and the installation of state-of-art technologies to support introduction of new products.
 
The new Asia Pacific Regional headquarters builds on an already strong manufacturing presence in Singapore, where the Company has recently completed a S$152 million (US$100 million) investment at their Tuas Biomedical Park facility to support future new product introductions, including an investigational medicine for lipid management (MK-524) that is currently in Phase III development. This brings Merck's total investments in Singapore to more than S$1 billion (US$650 million) in facilities that span 49 acres in Tuas, producing both active pharmaceutical ingredients as well as finished products for sale worldwide. Moving forward, the Company also plans to invest in additional new technology platforms at this facility to support more new product introductions.
 
The new regional office expands Merck's scope and capabilities in Singapore. The Company already employs over 500 people in its Singapore commercial and manufacturing operations.